49
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Rhegmatogenous Retinal Detachment: A Reappraisal of Its Pathophysiology and Treatment

      review-article

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This article represents a synthesis of an extensive literature review and the authors' decades-long personal experience with both scleral buckling (SB) and vitrectomy for rhegmatogenous retinal detachment (RD). Presenting a coherent understanding of the pathophysiology and treatment of RD, the authors confirm numerous findings described in earlier publications but also challenge certain long-standing dogmas. The key argument made here is that it is extremely rare for the chain of events leading to an RD to start with a retinal pathology. Rather, the initial pathology is syneresis of the vitreous, which then allows gel movement (intraocular currents). At the point of vitreoretinal adhesion, dynamic traction is exerted on the retina, which may be sufficient to tear it. If the tear is operculated and the dynamic traction overcomes the forces keeping the neuroretina and retinal pigment epithelium (RPE) together, the heretofore virtual subretinal space becomes accessible through the retinal tear. The intraocular currents allow the free (nonbound) intravitreal fluid to enter the subretinal space, and once the amount of the incoming fluid overwhelms the draining capacity of the RPE, an RD ensues. Detachment of the posterior cortical vitreous (PVD) is not a necessary prerequisite to RD development; furthermore, PVD cannot be diagnosed preoperatively with adequate certainty with current technology such as biomicroscopy, ultrasonography or optical coherence tomography. The surgeon should expect no or only partial (anomalous) PVD at the time of surgical repair in over half of eyes. The treatment's primary goal must thus be weakening (pneumatic retinopexy, SB) or eliminating (vitrectomy) this dynamic traction. If vitrectomy is employed, it must be a truly complete vitreous removal. This includes a surgically induced PVD if one is not present, close shaving at the periphery, and removing the vitreous immediately behind the lens. The vitrectomy is followed by the creation of a chorioretinal scar around the tear and aided by some form of intraocular tamponade. The main function of the tamponade is not to temporarily cover the break but to significantly reduce the intraocular currents and thus prevent fluid entry through the break until the chorioretinal adhesion will have become sufficiently strong to seal the retinal edge around the tear; postoperative positioning is therefore not as important as currently assumed.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Structural macromolecules and supramolecular organisation of the vitreous gel.

          The vitreous gel is a transparent extracellular matrix that fills the cavity behind the lens of the eye and is surrounded by and attached to the retina. This gel liquefies during ageing and in 25-30% of the oppulation the residual gel structure eventually collapses away from the posterior retina in a process called posterior retina in a process called posterior vitreous detachment. This process plays a pivotal role in a number of common blinding conditions including rhegmatogenous retinal detachment, proliferative diabetic retinopathy and macular hole formation. In order to understand the molecular events underlying vitreous liquefaction and posterior vitreous detachment and to develop new therapies it is important to understand the molecular basis of normal vitreous gel structure and how this is altered during ageing. It has previously been established that a dilute dispersion of thin (heterotypic) collagen fibrils is essential to the gel structure and that age-related vitreous liquefaction is intimately related to a process whereby these collagen fibrils aggregate. Collagen fibrils have a natural tendency to aggregate so a key question that has to be addressed is: what normally maintains the spacing of the collagen fibrils? In mammalian vitreous a network of hyaluronan normally fills the spaces between these collagen fibrils. This hyaluronan network can be removed without destroying the gel structure, so the hyaluronan is not essential for maintaining the spacing of the collagen fibrils although it probably does increase the mechanical resilience of the gel. The thin heterotypic collagen fibrils have a coating of non-covalently bound macromolecules which, along with the surface features of the collagen fibrils themselves, probably play a fundamental role in maintaining gel stability. They are likely to both maintain the short-range spacing of vitreous collagen fibrils and to link the fibrils together to form a contiguous network. A collagen fibril-associated macromolecule that may contribute to the maintenance of short-range spacing is opticin, a newly discovered extracellular matrix leucine-rich repeat protein. In addition, surface features of the collagen fibrils such as the chondroitin sulphate glycosaminoglycan chains of type IX collagen proteoglycan may also play an important role in maintaining fibril spacing. Furthering our knowledge of these and other components related to the surface of the heterotypic collagen fibrils will allow us to make important strides in understanding the macromolecular organisation of this unique and fascinating tissue. In addition, it will open up new therapeutic opportunities as it will allow the development of therapeutic reagents that can be used to modulate vitreous gel structure and thus treat a number of common, potentially blinding, ocular conditions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease.

            J. Sebag (2004)
            Posterior vitreous detachment (PVD) is the consequence of changes in the macromolecular structure of gel vitreous that result in liquefaction, concurrent with alterations in the extracellular matrix at the vitro-retinal interface that allow the posterior vitreous cortex to detach from the internal limiting lamina of the retina. Gel liquefaction that exceeds the degree of vitro-retinal dehiscence results in anomalous PVD (APVD). APVD varies in its clinical manifestations depending upon where in the fundus vitreo-retinal adhesion is strongest. At the periphery, APVD results in retinal tears and detachments. In the macula, APVD causes vitreo-macular traction syndrome, results in vitreoeschisis with macular pucker or macular holes, or contributes to some cases of diabetic macular edema. At the optic disc and retina, APVD causes vitreo-papillary traction and promotes retinal and optic disc neovascularization. Unifying the spectrum of vitreo-retinal diseases into the conceptual frame-work of APVD underscores that to more effectively treat, and ultimately prevent, these disorders it is necessary to replicate the two components of an innocuous PVD, i.e., gel liquefaction and vitreo-retinal dehiscence. Pharmacologic vitreolysis is designed to mitigate against APVD by chemically breaking down vitreous macromolecules and weakening vitro-retinal adhesion to safely detach the posterior vitreous cortex. This would not only facilitate surgery, but if performed early in the natural history of disease, it should prevent progressive disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Vitreoschisis

              J. Sebag (2008)
              «One does not see anything until one sees its beauty.» Oscar Wilde (1854–1900) Invisible by design [1, 2], vitreous is often overlooked as an important structure, until “one sees its beauty”. This remarkable structure is an extracellular matrix which has considerable importance in ocular health and disease [3]. Composed primarily of water, vitreous is nonetheless a solid gel in youth (Fig. 1), owing to the intricate association of collagen, hyaluronan, and other molecular components [4]. In youth, this exquisite structure is firmly adherent to the retina in a fascial (as opposed to focal) manner [5]. During aging, there are changes in vitreous macromolecular interactions that result in the formation of liquid vitreous, mostly comprised of hyaluronan and water, because the former is very hydrophyllic. Concurrently, there is aggregation of collagen fibrils into bundles of parallel fibers [6]. Vitreous liquefaction, known as “synchisis”, destabilizes vitreous and promotes its collapse, known as “syneresis” [7]. The impact of vitreous syneresis ranges from negligible to significant, depending upon the state of the vitreo–retinal interface [8]. Fig. 1 Human vitreous. The sclera, choroid, and retina were dissected off the vitreous in this autopsy specimen obtained form a 9-month-old girl. The vitreous remains attached to the anterior segment. Although the specimen rests upon a surgical towel in room air, the exquisite gel structure is maintained, owing to the young age of the donor. (Specimen courtesy of the New England Eye Bank) Previous theories of vitreo-retinal interface anatomy proposed that the collagen fibrils of the posterior vitreous cortex insert directly into the retina. However, it is currently recognized that interposed between the internal limiting lamina of the retina and the posterior vitreous cortex is an extracellular matrix ‘glue’ that consists of fibronectin, laminin, opticin, chondroitin sulfate, heparan sulfate, and other extracellular matrix constituents [4]. Another previously held belief was that the posterior vitreous cortex is a single layer of densely-packed collagen fibrils. However, recent studies by Hageman have shown that this may not always be the case. Indeed, immunohistochemistry has shown that the outer layer of vitreous has a lamellar structure, as shown in Fig. 2. Fig. 2 Vitreo–retinal interface. Imunohistochemical studies of the monkey vitreo–retinal interface employed fixation in 4% paraformaldehyde and staining with fluorescein-conjugated ABA lectin. The retina is at the bottom and the vitreous is at the top of this image. The intensely-stained, horizontal linear structure is the internal limiting lamina (ILL) of the retina. Above the ILL is the posterior vitreous cortex. The lamellar structure is clearly evident. Effective magnification ∼400x. (Courtesy of Greg Hageman, Ph.D.) The primary reason vitreous plays an important role in retinal diseases is that it is attached to the retina. Thus, the aging changes in vitreous that result in gel liquefaction may have untoward effects upon the retina in many cases. It is not known what initiates vitreous gel liquefaction, but some invoke metabolic and light-induced reactive oxygen species as the cause of conformational changes in vitreous macromolecules, resulting in dissociation of collagen from hyaluronan and the formation of liquid vitreous [9]. It is also not known what changes occur at the interface to weaken vitreo-retinal adhesion and promote vitreo-retinal dehiscence in the majority of individuals. However, what is known is that both of these two processes must occur simultaneously and in concert to result in an innocuous posterior vitreous detachment (PVD). Individuals who experience gel liquefaction without concurrent dehiscence at the vitreo-retinal interface may experience anomalous PVD [10]. Anomalous PVD can have a variety of manifestations (Fig. 3), depending upon where the gel vitreous is liquefied and where vitreo-retinal adhesion is strong. In the peripheral fundus, advanced gel liquefaction in the presence of strong vitreo-retinal adhesion causes retinal tears and detachments. Retinal lattice with overlying pockets of liquefied vitreous is a good example of peripheral anomalous PVD. At the optic disc, anomalous PVD can induce various vitreo-papillopathies, as well as play a role in promoting neovascularization and vitreous hemorrhage in ischemic retinopathies. At the macula, anomalous PVD can cause a variety of pathologies, depending upon whether or not the posterior vitreous cortex is intact (full thickness) or split (partial thickness). Full-thickness vitreous cortex adherence to the macula with peripheral vitreo-retinal separation can induce vitreo-macular traction, known as the vitreo-macular traction syndrome (VMTS). There is a broad, full-thickness posterior vitreous adhesion in VMTS, while the vitreo-foveal traction syndrome is caused by a more focal adhesion. In both instances, there is peripheral vitreo-retinal separation but persistent adhesion at the macula. The tractional forces are primarily antero-posterior, which induce retinal thickening with edema in the VMTS and a central cyst in the vitreo-foveal traction syndrome. Recent studies by Binder and colleagues in Vienna [11] have shown that in AMD, persistent vitreo-macular adhesion (that on OCT resembles VMTS) is associated with a significantly higher incidence of exudative AMD as compared to dry AMD (36% vs 7% respectively; P < 0.0001). A total PVD was found by ultrasonography in 72% of the eyes with dry AMD, as compared to 34% with exudative AMD (P = 0.0002) [11]. Fig. 3 Anomalous PVD. This schematic diagram demonstrates the various possible manifestations of anomalous PVD [10]. When gel liquefaction and weakening of vitreo–retinal adhesion occur concurrently, the vitreous separates away from the retina without sequelae (top of diagram). If the separation of vitreous from retina is full-thickness but incomplete, there can be different forms of partial PVD (right side of diagram). Posterior separation with persistent peripheral vitreo–retinal attachment can induce retinal breaks and detachments. Peripheral vitreo–retinal separation with persistent full-thickness attachment of vitreous to the retina posteriorly can induce traction upon the macula, known as the vitreo–macular traction syndrome (VMTS). This phenomenon appears to be highly associated with exudative AMD [11]. Persistent attachment to the optic disc can induce vitreo-papillopathies and also contribute to neovascularization and vitreous hemorrhage in ischemic retinopathies. If during PVD the posterior vitreous cortex splits (vitreoschisis), there can be differences depending upon the level of the split. Vitreoschsis anterior to the level of the hyalocytes leaves a relatively thick, cellular membrane attached to the macula. Inward (centripetal) contraction of this membrane induces macular pucker. If the split occurs at a level posterior to the hyalocytes, the remaining premacular membrane is relatively thin and hypocellular. Outward (centrifugal) tangential traction can induce a macular hole A split in the posterior vitreous cortex, known as vitreoschisis, induces a different set of vitreo–macular pathologies. Vitreoschisis is the consequence of anomalous PVD [10] with such strong vitreo–macular adhesion that when syneresis occurs, the posterior vitreous cortex splits, leaving the outermost layer attached to the macula, while the remainder of the vitreous collapses forward. This is believed to happen, at least in part, because of the underlying lamellar structure of the posterior vitreous cortex (Fig. 2). Balazs [12] first coined the term “vitreoschisis”, although what he described was actually not true vitreoschisis. Schepens and colleagues [13] were the first to diagnose vitreoschisis in patients with retino-vascular diseases using clinical biomicroscopy. Studies employing ultrasonography [14] and histopathology [15] have also detected vitreoschisis in proliferative diabetic retinopathy, and there is even a report of vitreoschisis in Eale’s disease [4, 16]. Recently, combined optical coherence tomography/scanning laser ophthalmoscopy (OCT/SLO; OPKO, Inc. Miami) was able to identify vitreoschisis clinically (Fig. 4). Indeed, studies [17] at the VMR Institute found that combined OCT/SLO imaging detected vitreoschisis in 53% of patients with macular holes and in 43% of patients with macular pucker. These studies led to the proposal that if the split occurs anterior to the level of hyalocytes, the remaining layer of vitreous will be relatively thick, hypercellular, and contractile. Contraction of this tissue causes inward (centripetal) tangential traction upon the underlying retina and results in macular pucker. If the split occurs posterior to the level of hyalocytes, a thin hypocellular membrane remains attached to the macula. If also attached to the optic disc, it may induce outward (centrifugal) tangential contraction, causing a macular hole. Fundamental to the theory of anomalous PVD with vitreoschisis is the hypothesis that the posterior vitreous cortex can indeed split into layers. Fig. 4 Clinical vitreoschisis. Combined OCT/SLO imaging detected a split in the posterior vitreous cortex. In these two cases, the outer layer of the split posterior vitreous cortex remains adherent to the retina. The point where the two layers re-join into one full-thickness layer is often the site of significant traction upon the retina. Studies have shown that about half of patients with macular hole and macular pucker have vitreoschisis In this issue of Graefe’s Archive for Clinical and Experimental Ophthalmology, Yamashita, Uemura, and Sakamoto present the first in vivo, intra-operative evidence of the occurrence of vitreoschisis. In this important study, 80% of eyes with macular pucker were found to develop vitreoschisis during vitrectomy surgery employing intra-operative triamcinolone to enhance visualization. Amongst those eyes that developed vitreoschisis intra-operatively, 58% had a visible ‘hole’ in the posterior vitreous cortex, while 42% of such eyes had no visible hole, suggesting that vitreoschisis can occur at various levels within the posterior vitreous cortex. This is consistent with the underlying multi-lamellar anatomy of the posterior vitreous (Fig. 2). These findings not only significantly contribute to our understanding of pathogenic mechanisms in vitreo-retinal disorders, but could also influence the performance of vitreo-retinal surgery. Knowing that the posterior vitreous cortex can split into layers (either pre-operatively or during surgery) can influence how aggressively one searches for membranes during membrane peeling. A higher index of suspicion in certain cases could also assist in the decision as to whether or not to employ surgical adjuncts like colored stains, such as indocyanine green and trypan blue, or particulate suspensions, such as the triamcinolone used by Yamashita and colleagues in their study. Selectively, more aggressive membrane dissection could also favorably impact upon the incidence of failed surgery and recurrences. Vitreoschisis may be present in a variety of other vitreo-retinal diseases. It is furthermore possible that at least part of the multi-lamellar structure present at the vitreo-retinal interface in pathologic eyes is the internal limiting lamina of the retina. Advances in imaging technology will hopefully provide ever more powerful methods with which to explore these possibilities. However, it is important to emphasize that the technologic developments that will provide these new diagnostic instruments must be matched by advances in our understanding and knowledge of vitreous anatomy and pathobiology, so that the new diagnostic technology will be used intelligently and productively. Investigators in this area are thus well-advise to recall that «What we see depends mainly on what we look for.» Sir John William Lubbock (1803–1865)
                Bookmark

                Author and article information

                Journal
                ORE
                Ophthalmic Res
                10.1159/issn.0030-3747
                Ophthalmic Research
                S. Karger AG
                0030-3747
                1423-0259
                2014
                December 2013
                22 October 2013
                : 51
                : 1
                : 15-31
                Affiliations
                aHelen Keller Foundation for Research and Education, Birmingham, Ala., USA; bMilos Eye Hospital, Belgrade, Serbia; cMoorfields Eye Hospital, London, UK
                Author notes
                *Ferenc Kuhn, MD, PhD, 2019 Hawkcrest Drive, St. Johns, FL 32259 (USA), E-Mail fkuhn@mindspring.com
                Article
                355077 Ophthalmic Res 2014;51:15-31
                10.1159/000355077
                24158005
                63cc7fed-567b-49db-8cd1-bf20129a5786
                © 2013 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 30 July 2013
                : 30 July 2013
                Page count
                Figures: 11, Tables: 4, Pages: 17
                Categories
                Review

                Vision sciences,Ophthalmology & Optometry,Pathology
                Vitrectomy,Treatment,Posterior vitreous detachment,Retinal detachment,Pathophysiology,Vitreoschisis,Vitreoretinal interface,Tamponade,Scleral buckling

                Comments

                Comment on this article